WO2010083253A3 - Cd47 related compositions and methods for treating immunological diseases and disorders - Google Patents

Cd47 related compositions and methods for treating immunological diseases and disorders Download PDF

Info

Publication number
WO2010083253A3
WO2010083253A3 PCT/US2010/020945 US2010020945W WO2010083253A3 WO 2010083253 A3 WO2010083253 A3 WO 2010083253A3 US 2010020945 W US2010020945 W US 2010020945W WO 2010083253 A3 WO2010083253 A3 WO 2010083253A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
methods
immunological diseases
related compositions
fusion polypeptides
Prior art date
Application number
PCT/US2010/020945
Other languages
French (fr)
Other versions
WO2010083253A2 (en
Inventor
Craig A. Smith
Steven Wiley
Ajamete Kaykas
Peter Probst
Original Assignee
Viral Logic Systems Technology Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viral Logic Systems Technology Corp. filed Critical Viral Logic Systems Technology Corp.
Publication of WO2010083253A2 publication Critical patent/WO2010083253A2/en
Publication of WO2010083253A3 publication Critical patent/WO2010083253A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.
PCT/US2010/020945 2009-01-14 2010-01-13 Cd47 related compositions and methods for treating immunological diseases and disorders WO2010083253A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14469509P 2009-01-14 2009-01-14
US61/144,695 2009-01-14
US17493909P 2009-05-01 2009-05-01
US61/174,939 2009-05-01

Publications (2)

Publication Number Publication Date
WO2010083253A2 WO2010083253A2 (en) 2010-07-22
WO2010083253A3 true WO2010083253A3 (en) 2010-12-29

Family

ID=42340280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/020945 WO2010083253A2 (en) 2009-01-14 2010-01-13 Cd47 related compositions and methods for treating immunological diseases and disorders

Country Status (1)

Country Link
WO (1) WO2010083253A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864290B (en) * 2017-05-08 2021-12-07 上海津曼特生物科技有限公司 Bispecific recombinant protein and application thereof

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9566347B2 (en) 2011-02-07 2017-02-14 The Trustees Of The University Of Pennsylvania Peptides and methods using same
CA2838478A1 (en) * 2011-06-16 2012-12-20 Novartis Ag Soluble proteins for use as therapeutics
CN110066341B (en) 2012-12-17 2023-01-31 Pf阿根图姆知识产权控股有限责任公司 Proteins, conjugates, pharmaceutical compositions, DNA constructs, host cells, and methods of making human SIRP alpha fusion proteins
US10329354B2 (en) 2013-09-18 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
ES2857109T3 (en) * 2015-05-18 2021-09-28 Ab Initio Biotherapeutics Inc SIRP Polypeptide Compositions and Methods of Use
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
EP3534964A4 (en) 2016-11-03 2020-07-15 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
JP7262440B2 (en) 2017-08-02 2023-04-21 フェインズ セラピューティクス，インコーポレーテッド Anti-CD47 antibody and uses thereof
TW201910349A (en) * 2017-08-10 2019-03-16 美商格里佛診斷方法股份有限公司 Compositions, methods and/or kits comprising a recombinant human CD38 extracellular region
EP3706775A4 (en) 2017-11-06 2021-09-01 Trillium Therapeutics Inc. Cd47 blockade with radiation therapy
JP7557920B2 (en) 2018-09-04 2024-09-30 ファイザー・インク CD47 blockade in combination with PARP inhibition for the treatment of disease - Patents.com
MX2021015452A (en) 2019-06-25 2022-02-11 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use.
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (en) 2019-10-31 2022-06-07 四十七公司 anti-CD 47 and anti-CD 20 based treatment of leukemia
US11845723B2 (en) 2019-12-24 2023-12-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
WO2022229818A1 (en) 2021-04-27 2022-11-03 Pf Argentum Ip Holdings Llc Enhancement of cd47 blockade therapy with dhfr inhibitors
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP2024522594A (en) 2021-06-23 2024-06-21 ギリアード サイエンシーズ， インコーポレイテッド Diacylglycerol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023073580A1 (en) 2021-10-29 2023-05-04 Pfizer Inc. Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy
WO2023079438A1 (en) 2021-11-08 2023-05-11 Pfizer Inc. Enhancement of cd47 blockade therapy with anti-vegf agents
WO2023110824A1 (en) * 2021-12-15 2023-06-22 Novo Nordisk A/S Novel integrin associated protein (iap)
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3239528A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
EP4245756B1 (en) 2022-03-17 2024-10-09 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (en) 2022-04-05 2023-12-01 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024159160A1 (en) * 2023-01-27 2024-08-02 The Board Of Trustees Of The Leland Stanford Junior University Combination adoptive immune cell and anti-cd47 therapy and related compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044857A1 (en) * 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Humanized anti-cd47 antibody
US20080131431A1 (en) * 2006-05-15 2008-06-05 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044857A1 (en) * 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Humanized anti-cd47 antibody
US20080131431A1 (en) * 2006-05-15 2008-06-05 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEBA 0. BARAZI ET AL.: "Regulation of Integrin Function by CD47 Ligands", JB C, vol. 277, no. 45, 8 November 2002 (2002-11-08), pages 42859 - 42866 *
XIJUN YU ET AL.: "Engagement of CD47 Inhibits the Contact Hypersensitivity Response Via the Suppression of Motility and B7 Expression by Langerhans Cells", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 126, 2 February 2006 (2006-02-02), pages 797 - 807 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864290B (en) * 2017-05-08 2021-12-07 上海津曼特生物科技有限公司 Bispecific recombinant protein and application thereof

Also Published As

Publication number Publication date
WO2010083253A2 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
WO2010083253A3 (en) Cd47 related compositions and methods for treating immunological diseases and disorders
WO2007133811A3 (en) Cd47 related compositions and methods for treating immunological diseases and disorders
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
WO2012016073A3 (en) Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
MX358137B (en) Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use.
MX348071B (en) Fc variants.
MX340971B (en) Monomeric antibody fc.
NZ728042A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
MX347077B (en) Active protease-resistant antibody fc mutants.
HK1209034A1 (en) Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function fc fc
WO2011028344A3 (en) Interleukin-1 receptor antagonist compositions and methods of making and using same
EA201290567A1 (en) PREPARATION OF HETEROLOGICAL POLYPEPTIDES IN MICROWATEREDES, EXTRA-CELLED MICROWAVE-ALONG CALVES, COMPOSITIONS AND METHODS OF THEIR RECEIVING AND APPLICATION
WO2014144960A3 (en) Fc variants
WO2010099219A3 (en) Designer ligands of tgf-beta superfamily
MX350273B (en) Fusion proteins for treating metabolic disorders.
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
WO2015007536A3 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
MX2012007318A (en) Tetravalent cd47-antibody constant region fusion protein for use in therapy.
PL2919801T3 (en) Stable pharmaceutical composition of the tnfr:fc fusion protein etanercept
IN2015DN01115A (en)
MY160995A (en) Polypeptides with permease activity
WO2009105669A3 (en) Angiogenesis inhibition
WO2011153276A3 (en) Stable, functional chimeric cellobiohydrolase class i enzymes
MX2012013735A (en) Neuregulin isoforms, neuregulin polypeptides and uses thereof.
WO2013183032A3 (en) Humanized anti-trka antibodies with amino acid substitutions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10732058

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10732058

Country of ref document: EP

Kind code of ref document: A2